CTC Detection and Enrichment Method Segment has the Largest Share of Technology in the Europe Circulating Tumor Cell (CTC) Diagnostics Market during 2021–2028

According to our latest study on “Europe Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Technology, Application, and End User,” the market is projected to reach US$ 957.8 million by 2028 from US$ 508.0 million in 2021; it is expected to grow at a CAGR of 9.5% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing prevalence of cancer across the region along with rising demand for minimally invasive diagnostic procedures. However, dearth of skilled professionals performing diagnostic procedures is expected to restrict the market growth during the forecast period.

The current coronavirus (COVID-19) outbreak has been declared by WHO as a Public Health Emergency of International Concern, according to the International Health Regulation. The COVID-19 emergency has undoubtedly aided in encouraging the general population to try out and expand their usage of digital services, particularly to avoid having to visit a health center in person. However, there are still a number of constraints that hinder these services from becoming more widely adopted. The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics for treating patients with the COVID-19. Consequently, according to one study, many diagnostic and treatment procedures had been cancelled or postponed around the world, including as many as 2.3 million cancer surgeries. Thus, the pandemic has a negative impact on Circulating Tumor Cell (CTC) Diagnostics market.

Based on technology, the circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. In 2021, the CTC detection and enrichment segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 10.2% in the forecast period.

Thermo Fisher Scientific, Stemcell Technologies, Inc, QIAGEN, Advanced Cell Diagnostics (Bio-Techne Corporation), Screencell, Ikonisys, Inc, and Fluxion Biosciences are among the leading companies in the Europe circulating tumor cell (CTC) diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for circulating tumor cell (CTC) diagnostics market is segmented into technology, application, and end user. Based on technology, the Europe circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection and CTC analysis. Based on application, the circulating tumor cell (CTC) diagnostics market is segmented into clinical/liquid biopsy, and research. Based on end user, the circulating tumor cell (CTC) diagnostics market is segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Geographically, the circulating tumor cell (CTC) diagnostics market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com